Psychology and Neuroscience Faculty Database
Psychology and Neuroscience
Arts & Sciences
Duke University

 HOME > Arts & Sciences > pn > Faculty    Search Help Login pdf version printable version 

Publications [#273501] of Richard S. Keefe

search PubMed.

Journal Articles

  1. Harvey, PD; Ogasa, M; Cucchiaro, J; Loebel, A; Keefe, RSE (2011). Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophrenia Research, 127(1-3), 188-194. [doi]
    (last updated on 2019/04/18)

    Background: Improving cognitive functioning in people with schizophrenia is a major treatment goal. In addition, interview-based measures have been developed to supplement performance-based assessments. However, few data are available regarding whether interview-based measures are sensitive to treatment-related changes. Methods: Adult outpatients who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomized to 21 days of double-blind treatment with lurasidone 120 mg once daily (N = 150) or ziprasidone 80 mg BID (N = 151). A similar proportion of patients completed the study on lurasidone (67.5%) and ziprasidone (69.3%). Study participants were assessed with the majority of the tests from the MATRICS Consensus Cognitive Battery (MCCB) and an interview-based assessment of cognitive functioning, the Schizophrenia Cognition Rating Scale (SCoRS). SCoRS ratings were based on the interviewer's best judgment, after interviews with the patient and a caregiver when available. The study was conducted from April 2006 to January 2007. Results: There were no between-group treatment differences in performance on the MCCB or the SCoRS ratings. Lurasidone patients demonstrated significant within group-improvement from baseline on the MCCB composite score (p = 0.026) and on the SCoRS (p < 0.001), but ziprasidone patients did not improve on either the MCCB composite (p = 0.254) or the SCoRS (p = 0.185). At endpoint there was a statistical trend (p = 0.058) for lurasidone to demonstrate greater improvement from baseline in SCoRS ratings. Improvements in interview-based aspects of cognition were not related to MCCB test changes, and had minimal correlations with changes in symptoms. Conclusions: These data suggest that interview-based cognitive measures such as the SCoRS may be sensitive to changes after 3 weeks of treatment in patients with schizophrenia. Lurasidone is being assessed further in ongoing clinical trials with additional outcome measures. © 2011 Elsevier B.V.

Duke University * Arts & Sciences * Faculty * Staff * Grad * Postdocs * Reload * Login